Literature DB >> 2038014

NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal.

J F Fries1.   

Abstract

Nonsteroidal antiinflammatory drug (NSAID) gastrointestinal (GI) pathology (gastropathy) accounts for over 70,000 hospitalizations and over 7,000 deaths annually in the United States. Not all patients, however, are at equal risk. Major risk factors for serious events (hospitalization or death) in patients with rheumatoid arthritis (RA) are age, level of disability, concurrent use of prednisone, prior NSAID side effects and NSAID dose. For the average patient with RA, the chance of hospitalization or death due to a GI event is about 1.3 to 1.6% over the course of 12 months and about 1 in 3 over the entire course of the disease. Subgroups of patients have risks ranging from nearly zero to as high as 4 or 5%/years. A simple scoring system based on multivariate analysis of risk factors permits the clinician to directly calculate the risk for the individual patient.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038014

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  36 in total

1.  Rheumatology: 4. Acute monoarthritis.

Authors:  J Cibere
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

Review 2.  Preventing NSAID-induced gastrointestinal toxicity. Economic considerations, methodological problems and results.

Authors:  G de Pouvourville
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

3.  Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly.

Authors:  Kathrine F Vandraas; Olav Spigset; Milada Mahic; Lars Slørdal
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

4.  Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study.

Authors:  Viktorija Erdeljic; Igor Francetic; Viola Macolic Sarinic; Marinko Bilusic; Ksenija Makar Ausperger; Mirjana Huic; Iveta Mercep
Journal:  Pharm World Sci       Date:  2006-11-17

Review 5.  A reader's guide to the evaluation of causation.

Authors:  T Podrebarac; P Tugwell; P C Hébert
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

Review 6.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 7.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

8.  The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.

Authors:  M J Al; B C Michel; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

9.  Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Authors:  Andrew Moore; Ceri Phillips; Elke Hunsche; James Pellissier; Simone Crespi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Comparison of in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions.

Authors:  H Kankaanranta; E Moilanen; H Vapaatalo
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.